

Vincenzo Di Nunno

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9308341/vincenzo-di-nunno-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

85
papers

818
citations

16
h-index

23
g-index

109
ext. papers

1,162
ext. citations

5.4
avg, IF

4.61
L-index

#	Paper	IF	Citations
85	Immune checkpoint inhibitors for metastatic bladder cancer. <i>Cancer Treatment Reviews</i> , 2018 , 64, 11-20	14.4	57
84	Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. <i>Cancer Treatment Reviews</i> , 2017 , 54, 68-73	14.4	52
83	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. <i>Tumori</i> , 2017 , 103, 405-421	1.7	31
82	Adjuvant therapy in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2017 , 60, 152-157	14.4	25
81	Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. <i>Targeted Oncology</i> , 2018 , 13, 705-714	5	24
80	Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. <i>Clinical Drug Investigation</i> , 2019 , 39, 503-519	3.2	23
79	Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers</i> , 2019 , 11,	6.6	21
78	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. <i>Immunotherapy</i> , 2019 , 11, 631-643	3.8	21
77	The Human Microbiota and Prostate Cancer: Friend or Foe?. <i>Cancers</i> , 2019 , 11,	6.6	20
76	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019 , 8,	7.9	20
75	Adjuvant Tyrosine Kinase Inhibitors in Treatment of Renal Cell Carcinoma: A Meta-Analysis of Available Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e339-e344	3.3	18
74	Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. <i>Cancer Treatment Reviews</i> , 2018 , 68, 80-85	14.4	18
73	New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e871-e877	3.3	18
72	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. <i>European Urology</i> , 2020 , 77, 761-763	10.2	18
71	BAP1 in solid tumors. <i>Future Oncology</i> , 2019 , 15, 2151-2162	3.6	17
70	Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. <i>Immunotherapy</i> , 2019 , 11, 1507-1521	3.8	15
69	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 397	5.3	15

68	Circulating tumor cells in genitourinary tumors. <i>Therapeutic Advances in Urology</i> , 2018 , 10, 65-77	3.2	14
67	Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2020 , 38, 105-106	2.2	13
66	Treatment of recurrent glioblastoma: state-of-the-art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 785-795	3.5	13
65	Tivozanib for the treatment of renal cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1021-1025	4.0	13
64	Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 1283-1289	3.8	12
63	Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 32-40	3.3	12
62	Key Role of Obesity in Genitourinary Tumors with Emphasis on Urothelial and Prostate Cancers. <i>Cancers</i> , 2019 , 11,	6.6	11
61	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018 , 129, 124-132	7	11
60	Toward a genome-based treatment landscape for renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 142, 141-152	7	11
59	Predictive markers of immune response in glioblastoma: hopes and facts. <i>Future Oncology</i> , 2020 , 16, 1053-1063	3.6	10
58	Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e83-e90	3.3	10
57	Atezolizumab for platinum-treated metastatic urothelial carcinoma. <i>Lancet, The</i> , 2018 , 391, 716-718	4.0	9
56	Molecular characterization and diagnostic criteria of renal cell carcinoma with emphasis on liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 141-150	3.8	9
55	The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017 , 2, 169-175	1.6	8
54	Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. <i>Future Oncology</i> , 2020 , 16, 1433-1439	3.6	8
53	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , 2020 , 40, 211-226	3.2	7
52	Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. <i>Oncologist</i> , 2021 , 26, 865-878	5.7	7
51	A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. <i>Molecular Diagnosis and Therapy</i> , 2019 , 23, 569-577	4.5	6

50	Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. <i>CNS Oncology</i> , 2021 , 10, CNS72	4	6
49	IDH1 Non-Canonical Mutations and Survival in Patients with Glioma. <i>Diagnostics</i> , 2021 , 11,	3.8	6
48	Cabazitaxel in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 1286	59.2	5
47	Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer. <i>Future Oncology</i> , 2018 , 14, 2559-2564	3.6	5
46	Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. <i>Anti-Cancer Drugs</i> , 2018 , 29, 710-715	2.4	5
45	Glioblastoma: Emerging Treatments and Novel Trial Designs. <i>Cancers</i> , 2021 , 13,	6.6	5
44	Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1333-1353	3.5	4
43	Immunotherapy and Radiation Therapy in Renal Cell Carcinoma. <i>Current Drug Targets</i> , 2020 , 21, 1463-1475	3.5	4
42	Rare Primary Central Nervous System Tumors in Adults: An Overview. <i>Frontiers in Oncology</i> , 2020 , 10, 996	5.3	4
41	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , 2016 , 27, 353-63	2.4	4
40	An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2020 , 20, 207-217	3.8	4
39	Glioblastoma Microenvironment: From an Inviolable Defense to a Therapeutic Chance.. <i>Frontiers in Oncology</i> , 2022 , 12, 852950	5.3	4
38	Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 1047-1059	5.4	3
37	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021 , 13, 419-432	3.8	3
36	IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment. <i>Molecular Diagnosis and Therapy</i> , 2021 , 25, 457-473	4.5	3
35	Re: Arnaud M Jean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?. <i>European Urology Oncology</i> , 2019 , 2, 340-341	6.7	3
34	Prostate cancer pathology: What has changed in the last 5 years. <i>Urologia</i> , 2020 , 87, 3-10	1.2	3
33	Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. <i>European Journal of Cancer</i> , 2021 , 145, 171-178	7.5	3

32	The role of precision medicine for the treatment of metastatic renal cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016 , 1, 369-377	1.6	2
31	Re: Gladell P. Paner, Walter M. Stadler, Donna E. Hansel, Rodolfo Montironi, Daniel W. Lin, Mahul B. Amin. Updates in the Eighth Edition of the Tumor-node-metastasis Staging Classification for Urologic Cancers. <i>Eur Urol</i> 2018;73:560-9: Tumour, Node, and Metastasis Staging System for Urological Malignancies. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018 , 7, 113-119	10.2	2
30	Identification of international metastatic renal cell carcinoma database consortium (IMDC) intermediate-risk subgroups in patients with metastatic clear-cell renal cell carcinoma. <i>Oncotarget</i> , 2020 , 11, 4582-4592	3.3	2
29	Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. <i>Advances in Therapy</i> , 2021 , 1	4.1	2
28	BET inhibitors: the promise of a new generation of immunotherapy in glioblastoma. <i>Immunotherapy</i> , 2021 ,	3.8	2
27	Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. <i>Diagnostics</i> , 2021 , 11,	3.8	2
26	Glioneuronal tumors: clinicopathological findings and treatment options. <i>Future Neurology</i> , 2020 , 15, FNL47	1.5	2
25	IDH1 single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas. <i>Pathology Research and Practice</i> , 2021 , 221, 153445	3.4	2
24	New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?. <i>European Urology Oncology</i> , 2019 , 2, 471	6.7	2
23	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019 , 17, 917-927	2.5	2
22	CheckMate 214 patient-reported outcomes: listening to our patients. <i>Lancet Oncology, The</i> , 2019 , 20, 179-180	21.7	2
21	A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. <i>Anti-Cancer Drugs</i> , 2018 , 29, 911-913	2.4	2
20	Pharmacotherapeutic Treatment of Glioblastoma: Where Are We to Date?. <i>Drugs</i> , 2022 , 82, 491	12.1	2
19	Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End. <i>European Urology Oncology</i> , 2019 , 2, 603-604	6.7	1
18	Nephrectomy after complete response to immune checkpoint inhibitors for metastatic renal cell carcinoma (mRCC): A new surgical challenge?. <i>Journal of Clinical Oncology</i> , 2020 , 38, 707-707	2.2	1
17	The clinical and prognostic role of ALK in glioblastoma. <i>Pathology Research and Practice</i> , 2021 , 221, 153447	3.7	1
16	Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue. <i>Future Oncology</i> , 2019 , 15, 563-565	3.6	1
15	Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. <i>Lancet</i> 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease. <i>European Urology Oncology</i> , 2020 , 3, 390	6.7	1

14	Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> 2018;73:62-8. <i>European Urology</i> , 2018 , 73, e72	10.2	1
13	Immune-checkpoint inhibitors in pituitary malignancies. <i>Anti-Cancer Drugs</i> , 2021 , 33,	2.4	1
12	Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 1265-1272	3.5	1
11	Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. <i>Lancet Oncol</i> 2018;19:405-15. <i>European Urology</i> , 2018 , 74, e50	10.2	0
10	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. <i>Tumori</i> , 2021 , 3008916211017213	1.7	0
9	Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF?. <i>Translational Andrology and Urology</i> , 2021 , 10, 1581-1587	2.3	0
8	Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer?. <i>Clinical Drug Investigation</i> , 2021 , 41, 757-773	3.2	0
7	Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04604	0.7	0
6	Improving IMDC criteria in patients with metastatic renal cell carcinoma through the addition of initial metastatic site in bone, brain, and liver.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 754-754	2.2	
5	PATH-15. NON-CANONICAL IDH 1 AND IDH 2 MUTATIONS ARE ASSOCIATED WITH IMPROVED SURVIVAL IN PATIENTS WITH GLIOMAS: RESULTS OF A META-ANALYSIS. <i>Neuro-Oncology</i> , 2021 , 23, vi117-vi118		1
4	Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 572-572	2.2	
3	MGMT methylation as a prognostic factor in IDH wild type anaplastic gliomas.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2523-2523	2.2	
2	Is combining PARP and androgen receptor inhibition really a winning strategy in metastatic castration-resistant prostate cancer?. <i>Lancet Oncology, The</i> , 2018 , 19, e437	21.7	
1	Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>Eur Urol</i> 2018;73:462-8. <i>European Urology</i> , 2018 , 74, e12-e13	10.2	